IAB produces and offers know-how, e.g. medical law, scales for rating movement disorders and therapy effects, reference books, videos, virtual products and guidelines.
The SARS-CoV-2 virus pandemic has provoked drastic countermeasures including shutdowns of public services. We wanted to describe the efects of a 6 week shutdown of a large German botulinum toxin (BT) outpatient clinics on patients and their well-being. ...
The PäPKi® method diagnoses and treats functional developmental disorders in babies and children (ICD10: F80.-83.) as well as functional disorders in adulthood.
The PäPKi® method diagnoses and treats functional developmental disorders in babies and children (ICD10: F80.-83.) as well as functional disorders in adulthood. ...
Published in the book: Botulinum Toxin Therapy Manual for Dystonia and Spasticity
Sorry, this entry is only available in Deutsch.
Sorry, this entry is only available in Deutsch.
Sorry, this entry is only available in Deutsch.
Sorry, this entry is only available in Deutsch.
INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES OTHER ACTS Guidelines of 7 March 2013 on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) English Version: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:068:0001:0014:EN:PDF German Version: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:068:0001:0014:DE:PDF Source: Official Journal of the European Union
Sorry, this entry is only available in Deutsch.
Sorry, this entry is only available in Deutsch.
Sorry, this entry is only available in Deutsch.
Sorry, this entry is only available in Deutsch.
(Deutsch) BUNDESSOZIALGERICHT Urteil vom 8.11.2011, B 1 KR 19/10 R Krankenversicherung - Verordnung eines Arzneimittels während und außerhalb eines arzneimittelrechtlichen Zulassungsverfahrens jenseits seiner bestehenden Zulassung nur bei wissenschaftlichen Erkenntnissen über Nutzen und Risiken des Mittels aufgrund von Phase III-Studien - Bindung von Hochschulambulanzen an die im ambulanten Bereich geltenden leistungsrechtlichen Begrenzungen des Anspruchs der Versicherten auf Versorgung mit Fertigarzneimitteln - kein Ersatz der Zulassungsentscheidung durch die bloße Möglichkeit einer Zulassung im Verfahren nach § 25b Abs 2 AMG 1976
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). ....
To provide decision support for everyday clinical practice, we develop evidence-based guidelines for Parkinson’s disease using international standards including AGREE. ....
INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES OTHER ACTS Guidelines of 7 March 2013 on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) English Version: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:068:0001:0014:EN:PDF German Version: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:068:0001:0014:DE:PDF Source: Official Journal of the European Union
a b s t r a c t: An interdisciplinary European group of clinical experts in the field of movement disordersand experienced Botulinum toxin users has updated the consensus for the use of Botu-linum toxin in the treatment of children with cerebral palsy (CP). ...
Abstract: Continuous intrathecal Baclofen application (ITB) through an intracorporeal pump system is widely used in adults and children with spasticity of spinal and supraspinal origin. Currently, about 1200 new ITB pump systems are implanted in Germany each year. ....
Abstract: Treatment of dystonias is generally symptomatic. To produce sufficient therapy effects, therefore, frequently a multimodal and interdisciplinary therapeutic approach becomes necessary, combining botulinum toxin therapy, deep brain stimulation, oral antidystonic drugs, adjuvant drugs and rehabilitation therapy including physiotherapy, occupational therapy, re-training, speech therapy, psychotherapy and sociotherapy ....
Abstract Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. ....
Abstract: Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. ....
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the management of spasticity in children with cerebral palsy (CP) for almost two decades. ....
a b s t r a c t An interdisciplinary European group of clinical experts in the field of movement disordersand experienced Botulinum toxin users has updated the consensus for the use of Botu-linum toxin in the treatment of children with cerebral palsy (CP). ....
Sorry, this entry is only available in Deutsch.
Goals for this presentation: Genetics, Anatomy, Physiology
Abstract When used therapeutically, botulinum toxin (BT) has to be injected into its target tissues. ...
3rd Chinese Botulinum Toxin Forum Back to Basic 2018
Marijuana - is a new billion dollar market emerging?
The brochure can be ordered from DyD for a fee of € 2. Selbsthilfeorganisation Dystonie-und-Du e. V. Volker Kreiss Madenburgweg 7 b 76187 Karlsruhe E-Mail: volker.kreiss@dysd.de Homepage: www.dysd.de
(Deutsch) Background: Rehabilitation interventions are rarely utilized as an alternative or adjunct therapy forfocal dystonias. Reasons for limited utilization are unknown, but lack of conclusive evidence of effectivenessis likely a crucial factor.
Objective: It is estimated that 4 million Americans with disabilities living in community settings use wheeled mobility devices and millions more access computers. Approximately 40% of these people cannot operate these devices adequately due to diminished upper-limb motor control, sensory limitations, and cognitive...
Abstract: Lesions of the central nervous system often result in an upper motor neuron syndromeincluding spasticity, paresis with pyramidal signs, and painful spasms. Pharmacologicaltreatment with oral antispasticity drugs is frequently associated with systemic side effects whichlimit their clinical use....
Background and Purpose: We sought to determine whether continuous intrathecal delivery of baclofen can effectivelydecrease spastic hypertonia due to stroke...
Abstract: Spasticity is very common in people with multi-ple sclerosis (MS). It is estimated that between 40 and60% of all patients are affected. ....
Abstract: Botulinum toxin A (BoNT-A) is considered a safe and effective therapy forchildren with cerebral palsy (CP), especially in the hands of experienced injectors and forthe majority of children. ....
Abstract: Current antispastic medications are unsatisfacto-ry for spasticity treatment,but botulinum toxin type A(BTX-A) shows promise as a new therapeutic option. ....
Objectives: To identify the drug treatments currently available for the management of spasticity and pain inmultiple sclerosis (MS), and to evaluate their clinical andcost-effectiveness ....
Preface The idea for this text ,International Neurology: A Clinical Approach, grew out of the involvement of the editors at the first two international neurology meetings held in Vietnam. ....
AIM We studied the incidence of incontinence and respiratory eventsin children withcerebralpalsy who received injections of botulinum toxin A (BoNT-A). ....
Introduction: The incidence of botulinum toxin type A (BoNT-A) injections related adverse effects (AE) is relatively high in literature. Many of injections are carried out yearly in our Physical andRehabilitation Medicine (PRM) unit, however only 4 adverse effects have been reported since 2010 ....
Abstract: A standardization of injection procedures for the various botulinum toxin (BoNT) indications has not been achieved to date. ....
Abstract: The aim of this study was to determine the safety profile of high dose (15–25 units/kg) of botulinum toxin A (BTX-A) in children with cerebral palsy (CP) and increased lower extremitymuscle tone. ....
To review the literature on primary dystonia and dystonia plus and to provide evidence-based recommendations. Primary dystonia and dystonia plus are chronic and often disabling conditions with a widespread spectrum mainly in young people. ....
Abstract: Equinus of the foot is the most common deformity in children with spasticcerebral palsy. Patients with cerebral palsy who are able to walk may havedifferent problems because of an equinus deformity. ....
Abstract – We evaluated the safety ans effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). ....
Abstract: Pes cavus in Charcot–Marie–Tooth disease type1A (CMT1A) is thought to be due to muscle imbalance of thelower leg. Botulinum toxin type A (BoNT-A) can modify foot de-formity in other conditions of muscle imbalance. ....
Background: Use of Botulinum toxin-A (BoNT-A) for treatment of upper limb spasticity in children with cerebral palsyhas become routine clinical practice in many paediatric treatment centres worldwide. ...
AIM: To give an overview of indications for the use of botulinum toxin A (BoNT-A) treatment forchildren with obstetric brachial plexus injury (OBPI), and topresent the best availableevidence of the effectiveness of this treatment. ...
This study compared the effects of low and high doses of botulinum toxin A (BTX-A) to improve upper extremityfunction. ...
Background: Botulinum toxin type A is a first-line treatment for post-stroke focal spasticity, and the accuracy in delivering the toxin to the target muscles may influence the treatment outcome. Our aim was to compare the reduction of spasticity and the related finger position at rest improvement in post-stroke patients treated with botulinum toxin type A in upper limb muscles using ultrasound guidance and manual needle placement. ...
Oromandibular dystonia (OMD) refers to involuntary spasms of masticatory,lingual and pharyngeal muscles. ...
To review theliterature on primarydystoniaanddystoniaplusandtoprovideevidence-based recommendations. ...
Background: Dystonia and spasticity are common symptoms in children with Cerebral Palsy(CP), whose management is a challenge to overcome in order to enable the harmonized development of motor function during growth. ...
Abstract: A standardization of injection procedures forthe various botulinum toxin (BoNT) indications has notbeen achieved to date. ...
Purpose: Botulinum A toxin (BoNT-A) injections are used widely to manage lower extremityspasticity in children with cerebral palsy. ...
Abstract: The aim of this study was to determine the safety profile of high dose (15–25 units/kg) of botulinum toxin A (BTX-A) in children with cerebral palsy (CP) and increased lower extremity muscle tone. ...
Adductor spasticity in children with cerebral palsy (CP) impairsmotor function and development. ...
Introduction: The incidence of botulinum toxin type A (BoNT-A) injections related adverse effects(AE) is relatively high in literature. Many of injections are carried out yearly in our Physical and Rehabilitation Medicine (PRM) unit, however only 4 adverse effects have been reported since 2010. ...
Abstract: Huntington’s disease (HD) produces debilitating motor abnormalities that are poorly responsive to medicaltherapy. ...
AIM: We studied the incidence of incontinence and respiratory events in children with cerebral palsy who received injections of botulinum toxin A (BoNT-A). ...
Two cases of idiopathic chondrolysis were treated bybotulinum neurotoxin-A injections, with a favorableoutcome. ...
Oromandibular dystonia (OMD) refers to involuntary spasms of masticatory,lingual and pharyngeal muscles. ...
Background: The controlled evidence favoring botulinum toxin A (BtA) treatment for spasticity incerebral palsy is based on short-term studies. ...
Background: Cerebral palsy (CP) is a central nervous system deficit resulting from a non-progressive lesion in the developing brain. ...
Abstract: Spasticity is very common in people with multi-ple sclerosis (MS). ...
Abstract: A standardization of injection procedures for the various botulinum toxin (BoNT) indications has not been achieved to date. ...
Background: Cerebral palsy is the most common cause of physical disability in childhood. Spasticity is a significant contributor to the secondary impairments impacting functional performance and participation. ...
Objective: To compare the effect of equivalent doses in two different volumesof botulinum toxin type A (Dysport) on gastrocnemius spasticity. ...
Objective: To compare the outcome of manual needle placement, electrical stimulation and ultrasonography-guided techniques for botulinum toxin injection into the forearm muscles of adults with arm spasticity....
Objective: To compare the effectiveness of two procedures increasing the botulinum toxin type A effect for wrist and finger flexor spasticity after stroke. ...
Background: Therapeutic ultrasound and transcutaneous electrical nerve stimulation (TENS) have been described asbeing effective in the treatment of spasticity. ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the management of spasticity in children with cerebral palsy (CP) foralmost two decades. ...
Abstract: Hereditary spastic paraplegia (HSP) is characterizedby lower extremity spasticity. Symptomatic therapy generallyincludes physical therapy and oral antispastic agents, in se-lected cases intrathecal baclofen. ...
Purpose: A pilot study with short-term outcomes of acombinedsurgicalandmedicalinterventionformanagementof generalized lower limb spasticity, hip displacement andcontractures of adductors in children with bilateral spasticcerebral palsy. ...
Publication List
Publication List
Publication List
Publication List
Publication List
Publication List
Publication List
Books of very experienced experts can be of tremendous benefit to therapists, but also to interested patients alike. A selection of reference books for patients and relatives as well as for physicians and health professionals are compiled here and offered for sale
The success of a complex therapy of chronic conditions with several therapists involved is decisively determined by the exact documentation of the processes and their effect. This documentation is in the hands of the patient between visits to the physician. IAB selects, produces and sells ratings scales for movement disorders and therapy effects. Some are […]
Movement Disorders bear some of the most intriguing mysteries yet to discover. Our recorded experts are among the best known scientists working on these topics being right in the centre of it all. who could better answer our questions as? IAB produces videos with internationally outstanding scientists on the subject of movement disorders of great historical value.